(R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them
The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.
1. (R)-4-(heteroaryl)phenylpropionic compounds of formula (I):
and pharmaceutically acceptable salts thereof, wherein
X is a heteroatom selected from
S, O and N
Y is H or a residue selected from the group consisting of:
halogen, linear or branched C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 1 -C 4 -alkoxy, hydroxy, —COOH, C 1 -C 4 -acyloxy, phenoxy, cyano, nitro, —NR 2 , C 1 -C 4 -acylamino, halo-C 1 -C 3 -alkyl, benzoyl, linear or branched C 1 -C 8 -alkanesulfonate, linear or branched C 1 -C 8 -alkanesulfonamides, linear or branched C 1 -C 8 -alkyl sulfonylmethyl;
Z is an heteroaryl ring selected from the group consisting of:
unsubstituted tetrazole and
triazole, pyrazole, oxazole, thiazole, isooxazole, isothiazole, thiadiazole and oxadiazole substituted by one hydroxy group and optionally further substituted by one or more goups selected from the group consisting of halogen, linear or branched C 1 -C 4 -alkyl, C 2 -C 4 -alkenyl, C 1 -C 4 -alkylamino, C 1 -C 4 -alkoxy, C 1 -C 4 -alkylthio, C 1 -C 4 -acyloxy, cyano, nitro, NH 2 , C 1 -C 4 -acylamino, halo-C 1 -C 3 -alkyl, halo-C 1 -C 3 -alkoxy, linear or branched C 1 -C 8 -alkanesulfonate and linear or branched C 1 -C 8 -alkanesulfonamides.
2. Compounds according to claim 1 wherein:
X is a heteroatom selected from
S and O
Y is H or a residue selected from the group consisting of:
halogen, linear or branched C 1 -C 4 -alkyl and halo-C 1 -C 3 -alkyl;
Z is an heteroaryl ring selected from the group consisting of:
unsubstituted tetrazole and
triazole, pyrazole, isooxazole, isothiazole, thiadiazole and oxadiazole substituted by one hydroxy group and optionally further substituted by one or more groups selected from the group consisting of halogen, linear or branched C 1 -C 4 -alkyl, C 1 -C 4 -alkylthio and halo-C 1 -C 3 -alkyl.
3. Compounds according to claim 1 , wherein:
Y is H or a residue selected from the group consisting of trifluoromethyl, chlorine, methyl and tert-butyl.
4. Compounds according to claim 1 , wherein
said triazole, pyrazole, isooxazole, isothiazole, thiadiazole or oxadiazole ring is substituted by one hydroxy group and optionally further substituted by one or more groups selected from the group consisting of methyl, trifluoromethyl and chlorine.
5. Compounds according to claim 1 , selected from the group consisting of:
N-{4-[(1R)-1-(1H-tetrazol-5-yl)ethyl]phenyl}-4-(trifluoromethyl)-1,3-thiazol-2-amine;
4-methyl-N-{4-[(1R)-1-(1H-tetrazol-5-yl)ethyl]phenyl}-1,3-thiazol-2-amine;
4-tert-butyl-N-{4-[(1R)-1-(1H-tetrazol-5-yl)ethyl]phenyl}-1,3-thiazol-2-amine;
N-{4-[(1R)-1-(1H-tetrazol-5-yl)ethyl]phenyl}-1,3-thiazol-2-amine;
N-{4-[(1R)-1-(1H-tetrazol-5-yl)ethyl]phenyl}-4-(trifluoromethyl)-1,3-oxazol-2-amine;
4-methyl-N-{4-[(1R)-1-(1H-tetrazol-5-yl)ethyl]phenyl}-1,3-oxazol-2-amine;
5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1H-pyrazol-1-ol;
4-methyl-5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1H-pyrazol-1-ol;
5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1H-1,2,3-triazol-1-ol;
5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]isoxazol-3-ol;
4-methyl-5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]isoxazol-3-ol;
5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]isothiazol-3-ol;
4-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1,2,5-oxadiazol-3-ol;
4-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1,2,5-thiadiazol-3-ol;
5-[(1R)-1-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-1H-1,2,4-triazol-1-ol.
6. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 in combination with at least one pharmaceutically acceptable excipient and/or a diluent.
7. A method for the treatment of diseases involving C5a induced human PMNs chemotaxis, wherein said diseases are selected from the group consisting of: autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis glomerulonephritis, injury caused by ischemia and reperfusion, comprising administering to a patient in need thereof the pharmaceutical composition according to claim 6 .
8. A method for prevention of injury caused By ischemia and reperfusion, comprising administering to a patient in need thereof the pharmaceutical composition according to claim 6 .
9. Process for the preparation of compounds of claim 1 , wherein Z is tetrazole, comprising the reaction of compound of formula (II),
wherein X and Y have the same meaning as defined in claim 1 , with trimethylsilylazide, affording the corresponding tetrazoles of formula (I).
10. A method for reducing the risk of injury caused by ischemia and reperfusion, comprising administering to a patient in need thereof the pharmaceutical composition according to claim 6 .